Dr. R. M. Pérez Carrión Octubre 2007 CONCLUSIONES Dr. R. M. Pérez Carrión Octubre 2007

Patient Subgroups of Interest for Erlotinib-Based Therapy Patients Subgroup Observations Avoidance of Chemotherapy associated toxicity desirable in this patient subgroup, demonstration of Erlitinib activity in patients with poor PS. However, in a direct comparison in a general patient cohort with PS of 2, chemotherapy demonstrated higher efficacy of Erlotinib. Likely to have activating EGFR mutations; smoking history highly predictive of benefit from Erlotinib. Activating mutations in the EGFR gene highly predictive of response to Erlotinib. Activity of EGFR TKIs in patients with BAC histology. High frequency of EGFR mutations in patients with brain metastases. Poor performance status Never- smokers Activating EGFR Mutations Bronchioalveolar Carcinoma Brain Metastases Ramón Pérez Carrión, Antonio Cubillo Gracián, Pedro Salinas Hernández Clinical Lung Cancer July 2007 . Vol. 8 nº 7 425-428

¿Disponemos de un marcador molecular realmente eficaz predictivo de beneficio clínico?

CÁNCER DE PULMÓN: NUEVAS MOLÉCULAS 1ª Línea Bevacizumac. ECOG 4598 /estudio fase III Erlotinib. Paz Ares y col. ASCO 2006. Fase II. Estudio Target

CÁNCER DE PULMÓN: NUEVAS MOLÉCULAS 2ª Línea Erlotinib Gefitinib. Estudio fase III, INTEREST

Phase II, randomized, open-label, parallel-group study of oral Gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST) J. Y. Douillard, E. S. Kim, V. Hirsh, T. Mok, M. Socinski, R. Gervais, L. Y. WU, L. Li, M. Sellers, E. Lowe ECCO 2007. Presidential Sessions European Journal of Cancer. Supplements Vol 5, nº 7 . 2LB

CÁNCER DE PULMÓN: NUEVAS MOLÉCULAS 3ª Línea Subgrupo PS2 Subgrupo ancianos ……….

Ramón Pérez Carrión, Antonio Cubillo Gracián, Pedro Salinas Hernández Erlotinib as single agent in select subsets of patients with advanced non-small-cell Lung cancer Ramón Pérez Carrión, Antonio Cubillo Gracián, Pedro Salinas Hernández Clinical Lung Cancer July 2007 . Vol. 8 nº 7 425-428

Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC Alberola, Vicente; Gallego, Oscar; López-Vivanco, Guillermo: Mesía, Carlos; Oramas, Juana; Trigo, José Manuel; Virizuela, J. Antonio; Camps, Carlos; Amador, Mª Luz; Massutí, Bartomeu XII World Conference on Lung Cancer Journal of Thoracic Oncology Volume 2, nº 8, supplement 4, august 2007 S703

García-Velasco, Adelaida; Pérez Carrión, Ramón; Erlotinib as third and successive line of treatment in advanced or metastatic NSCLC García-Velasco, Adelaida; Pérez Carrión, Ramón; de Castro, Javier; Garrido, Pilar: García, Ramón; González Larriba, J. Luis; Martín, Germán; Provencio, Mariano; Regueiro, Pilar; Massutí, Bartomeu XII World Conference on Lung Cancer Journal of Thoracic Oncology Volume 2, nº 8, supplement 4, august 2007 S713